-
Dabigatran Workflows for Thrombin Assays
2026-09-21
Build more interpretable anticoagulation experiments with Dabigatran, from thrombin generation testing to orthogonal coagulation function assays. The workflow distinguishes parent Dabigatran from its less potent metabolite DABG and provides practical controls for solubility, assay timing, and matrix effects.
-
CCK-8, Endogenous Opioids, and Morphine-Withdrawal Anxiety
2026-09-21
The reference study shows that cholecystokinin octapeptide (CCK-8) reduces anxiety-like behavior during morphine withdrawal through CCK1 receptor signaling and endogenous opioid mechanisms. Its pharmacological design separates CCK1 activity from μ-opioid involvement, providing a useful framework for opioid addiction and withdrawal studies while highlighting the limits of translating elevated-plus-maze behavior directly to clinical anxiety.
-
Cabazitaxel (XRP6258): Resistant Model Protocol
2026-09-20
Cabazitaxel (XRP6258; SKU B2157) is a semi-synthetic taxane derivative for studying antiproliferative responses and microtubule dynamics disruption, including in P-glycoprotein-expressing or taxane-resistant cancer models. It is suited to carefully controlled DMSO- or ethanol-based workflows, but it is insoluble in water and prepared solutions should be used promptly rather than stored long term.
-
Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT
2026-09-19
The reference study integrates network pharmacology with cellular and animal experiments to investigate how Shenqi Fuzheng injection affects glioma proliferation and migration. Its results identify SRC/PI3K/AKT signaling as a plausible regulatory axis and connect computational target mapping with S-phase arrest, reduced migration, epithelial–mesenchymal transition marker changes, and smaller transplanted tumors.
-
Refining In Vitro Drug Response Metrics in Cancer
2026-09-19
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent outcomes. This framework encourages time-aware, mechanism-conscious assay design and more cautious interpretation of anticancer activity in cell-based studies.
-
BCS Biowaiver Evidence for Taltirelin ODTs
2026-09-18
Ono and Sugano evaluated whether dissolution testing could support a BCS-based biowaiver for orally disintegrating tablets compared with immediate-release formulations of BCS class III drugs. Taltirelin and olopatadine met the relevant dissolution criteria, while results for four other drugs showed that dose-to-solubility ratio and formulation-specific dissolution behavior remain important when interpreting bioequivalence.
-
SR 11302: Translating AP-1 Biology Into Cancer Strategy
2026-09-18
SR 11302 provides a mechanistically focused route to interrogate AP-1-driven tumor biology without directly activating RAR or RXR. This thought-leadership analysis connects its cancer-cell data with macrophage and TLR4 findings in colitis-associated colorectal cancer, while defining practical assay, translational, and evidence boundaries.
-
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) Workflow
2026-09-17
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) supports transient Cas12a expression for research workflows that benefit from a single crRNA, T-rich PAM recognition, and PAM-distal staggered cleavage. This practical guide connects product selection with guide design, delivery optimization, editing quantification, and troubleshooting while separating published evidence from starting recommendations.
-
7-dehydro Cholesterol: Assay Workflows
2026-09-17
Use 7-dehydro Cholesterol to connect DHCR7 activity, UVB-driven vitamin D3 formation, sterol oxidation, and disease-relevant lipid remodeling in one experimental framework. A practical workflow also shows how chemical substrate exposure can complement, but not replace, genetic studies of DHCR7-linked antiviral phenotypes.
-
IBDV VP3 Drives IRF7 Proteasomal Loss
2026-09-16
The 2025 Frontiers in Cellular and Infection Microbiology study identifies IBDV VP3 as a viral factor that suppresses IRF7-dependent type I interferon signaling by promoting IRF7 loss through the proteasome pathway. Its infection, gain-of-function, loss-of-function, and protein-interaction experiments provide a mechanistic framework for understanding how very virulent IBDV evades antiviral defense, while also defining important limits for applying E1 or proteasome perturbation tools.
-
Thapsigargin for Reproducible Cell Assays
2026-09-15
Learn how Thapsigargin (SKU B6614) helps researchers connect SERCA inhibition with calcium signaling, ER stress, apoptosis, and cell viability outcomes. This scenario-based guide covers assay design, optimization, interpretation, and practical product-selection criteria.
-
Hydrocortisone Butyrate: From GR Biology to Delivery
2026-09-15
Hydrocortisone butyrate is more than a glucocorticoid receptor agonist for inflammation assays. This guide connects receptor biology, dermatitis and epidermal models, and PLGA-based delivery research while showing why ester stability and exposure design determine translational interpretation.
-
MK 0893: From Receptor Binding to In Vivo Readouts
2026-09-14
MK 0893 is a glucagon receptor antagonist whose allosteric pharmacology connects nanomolar receptor binding with measurable metabolic effects. This article offers an assay-to-animal framework for interpreting MK 0893 in type 2 diabetes research, with emphasis on endpoint selection, selectivity, and translational limits.
-
N2703 for Causal Cardiac Signaling Assays
2026-09-14
Explore how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) can be evaluated in mechanism-focused cardiac models without overstating its biology. This guide translates adipose-neural arrhythmia research into rigorous assay design, controls, and interpretation.
-
Structural Insights into CD38 CAR Affinity Tuning
2026-09-13
This iScience study compares how the CAR binders RP02 and 028 engage CD38, revealing distinct epitope geometries, effects on enzymatic activity, and opportunities for rational affinity tuning. Its affinity-attenuated 028R103G design reduced CAR-T fratricide while preserving cytotoxicity against CD38-positive tumor cells, supporting structure-guided optimization of CD38-directed therapy.